In this study the authors of the paper "Increased RET activity coupled with a reduction in the RET gene dosage causes intestinal aganglionosis in mice" use advanced transgenic technologies to study the effect of RET51(C618F) mutant, an activating mutation identified in MTC patients, in the development of ENS. This evidence concerns the gene RET and medullary thyroid gland carcinoma.